Associations between lifetime classic psychedelic use and cardiometabolic diseases
Otto Simonsson1,2, Walter Osika3,4,5, Robin Carhart-Harris6
1Department of Sociology, University of Oxford, Oxford, UK. otto.simonsson@trinity.ox.ac.uk.
Abstract:
The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005-2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes. Respondents who reported having tried a classic psychedelic at least once in their lifetime had lower odds of heart disease in the past year (adjusted odds ratio (aOR) = 0.77 (0.65-0.92), p = .006) and lower odds of diabetes in the past year (adjusted odds ratio (aOR) = 0.88 (0.78-0.99), p = .036). Classic psychedelic use might be beneficial for cardiometabolic health, but more research is needed to investigate potential causal pathways of classic psychedelics on cardiometabolic diseases.
More Related Videos
Related Concept Videos
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Coronary Artery Disease I: Introduction
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Hallucinogens and Psychedelics
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
Cardiomyopathy III: Hypertrophic Cardiomyopathy


